Abstract PO-033: Qualitative analysis of the lifestyle programming preferences of Mexican-origin breast cancer survivors and cancer caregivers living on the U.S./Mexico border

Author(s):  
Samantha J. Werts ◽  
Melissa Lopez-Pentecost ◽  
Meghan Skiba ◽  
Rosi Vogel ◽  
Maia Ingram ◽  
...  
2020 ◽  
Vol 26 (9) ◽  
pp. 827-834
Author(s):  
Kamila Osypiuk ◽  
Karen Kilgore ◽  
Jennifer Ligibel ◽  
Gloria Vergara-Diaz ◽  
Paolo Bonato ◽  
...  

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e24038-e24038
Author(s):  
Lisellet Morin ◽  
Noah Zanville ◽  
Rosalind Guest ◽  
Muni Rubens ◽  
M. Beatriz Currier

e24038 Background: Early detection and a growing complement of treatment options have led to improved survival among women with breast cancer in the U.S. Vasomotor symptoms (VMS) such as hot flashes and night sweats are among the most common side effects reported by breast cancer survivors (BCS) following treatment. These symptoms may affect quality of life and increase the risk of non-adherence to anti-hormonal therapies. Hispanics are one of the fastest growing ethnic populations in the U.S. However, research exploring whether Hispanic BCS report VMS at similar rates as their non-Hispanic counterparts remains an important gap in the science. The purpose of this study was to compare the prevalence and risk factors for VMS between Hispanic and non-Hispanic BCS following cancer treatment. Methods: Data for this single-center, retrospective study came from a database of self-reported symptom data collected at survivorship visits. Results: Over a 2.8-year period, 815 female BCS were evaluated for VMS (Hispanic: 63.0% (n=513) vs. Non-Hispanic: 37.0% (n = 302)). Mean age of the sample was 58.4 + 11.7 (range 24.2 - 91.8).Approximately four in ten (42.9%) BCS reported VMS at their initial survivorship visit, 0-3 years post-treatment. Results found virtually no difference in VMS prevalence between Hispanic and non-Hispanic BCS, (42.5% vs 43.7%, p = 0.735). BCS who reported VMS after treatment were 6.5 years younger, on average, than BCS who did not report VMS (54.7 ±11.0 vs. 61.2 ±11.3, p < 0.001). Multivariate logistic regression models using age, race, stage of cancer, chemotherapy, radiation and hormone therapy as predictors showed that only age was associated with reporting VMS. For every one-year increase in age, the odds of reporting VMS fell by approximately 5.3% (OR: 0.947, 95% CI: 0.933-0.963, p < 0.0001). Conclusions: Results found no difference in VMS prevalence between Hispanic and non-Hispanic BCS. VMS were reported by over 40 % of BCS in the study. In addition, symptoms were more prevalent in younger BCS. Given the potential impact of VMS on quality of life and mediation adherence, studies validating these findings as well as exploring the prevalence and risk factors for VMS in Hispanic BCS from distinct nationalities and cultures are needed.


2014 ◽  
Vol 19 (8) ◽  
pp. 814-822 ◽  
Author(s):  
Katrina F. Trivers ◽  
Aliza K. Fink ◽  
Ann H. Partridge ◽  
Kutluk Oktay ◽  
Elizabeth S. Ginsburg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document